Global Personalized Medicine and Cell Therapy Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Personalized Medicine and Cell Therapy Market Size

• The global personalized medicine and cell therapy market size was valued at USD 7.92 billion in 2024 and is expected to reach USD 21.72 billion by 2032, at a CAGR of 13.44% during the forecast period
• The market growth is primarily driven by advancements in precision medicine, increasing adoption of targeted therapies, and growing investment in cell-based treatments, leading to enhanced patient outcomes in various medical fields
• Rising consumer demand for tailored healthcare solutions, coupled with technological advancements in diagnostics and therapeutics, is establishing personalized medicine and cell therapy as a cornerstone of modern healthcare systems

Personalized Medicine and Cell Therapy Market Analysis

• Personalized medicine and cell therapy involve tailoring medical treatment to individual patient characteristics, leveraging genetic, proteomic, and cellular data to enhance treatment efficacy and safety
• The demand for personalized medicine and cell therapy is fueled by increasing prevalence of chronic diseases, advancements in genomic research, and growing consumer awareness of customized healthcare solutions
• North America dominated the personalized medicine and cell therapy market with a revenue share of 40.01% in 2024, driven by early adoption of precision medicine, robust healthcare infrastructure, high investment in research and development, and the presence of leading biotech companies
• Asia-Pacific is expected to be the fastest-growing region during the forecast period, propelled by increasing healthcare expenditure, rising prevalence of chronic diseases, and rapid advancements in biotechnology and genomics
• The personalized nutrition and wellness segment dominated the largest market revenue share of 48.40% in 2024, driven by its widespread adoption for tailored health recommendations based on genetic, phenotypic, and lifestyle data, enhancing preventive care and long-term health outcomes

Report Scope and Personalized Medicine and Cell Therapy Market Segmentation   

Personalized Medicine and Cell Therapy Market Trends

Increasing Integration of AI and Big Data Analytics

• The global personalized medicine and cell therapy market is experiencing a significant trend toward integrating Artificial Intelligence (AI) and Big Data analytics
• These technologies enable advanced data processing and analysis, providing deeper insights into patient health profiles, treatment efficacy, and disease progression
• AI-powered personalized medicine solutions facilitate proactive treatment strategies, identifying potential health risks before they escalate into severe conditions
  • For instance, companies are developing AI-driven platforms that analyze genetic and proteomic data to tailor therapies or optimize treatment plans based on real-time patient data and environmental factors
• This trend enhances the value proposition of personalized medicine and cell therapy, making them more appealing to healthcare providers, patients, and research institutions
• AI algorithms can analyze vast datasets of patient biomarkers, including genetic mutations, protein expressions, and lifestyle factors, to support precision diagnostics and treatment

Personalized Medicine and Cell Therapy Market Dynamics

Driver

Rising Demand for Precision Medicine and Advanced Therapeutic Solutions

• Increasing consumer and healthcare provider demand for precision medicine, such as targeted therapies, personalized diagnostics, and wellness solutions, is a major driver for the global personalized medicine and cell therapy market
• Cell therapy and personalized medicine enhance patient outcomes by offering tailored treatments, such as stem cell therapies for regenerative medicine and pharmacogenomics-based drug prescriptions
• Government initiatives and funding, particularly in North America, which dominates the market, are contributing to the widespread adoption of personalized medicine technologies
• The proliferation of advanced biotechnologies and the development of high-throughput sequencing and point-of-care testing are further enabling market expansion, offering faster and more accurate diagnostic and therapeutic capabilities
• Healthcare providers and pharmaceutical companies are increasingly integrating personalized medicine and cell therapy solutions as standard or optional offerings to meet patient expectations and improve clinical outcomes

Restraint/Challenge

High Cost of Implementation and Data Privacy Concerns

• The substantial initial investment required for developing and integrating personalized medicine and cell therapy technologies, including diagnostics, therapeutics, and research infrastructure, can be a significant barrier to adoption, particularly in emerging markets such as parts of Asia-Pacific, despite it being the fastest-growing region
• Implementing advanced technologies such as pharmacogenomics and stem cell therapy into existing healthcare systems can be complex and costly
• Data security and privacy concerns pose a major challenge, as personalized medicine and cell therapy rely on collecting and analyzing vast amounts of sensitive patient data, raising risks of breaches, misuse, or non-compliance with regulations such as GDPR or HIPAA
• The fragmented regulatory landscape across countries regarding genetic data collection, storage, and usage complicates operations for global manufacturers and service providers
• These factors can deter adoption and limit market expansion, particularly in regions with high awareness of data privacy or where cost sensitivity is a significant factor

Personalized Medicine and Cell Therapy market Scope

The market is segmented on the basis of product, technology, application, and end-user.

• By Product

On the basis of product, the global personalized medicine and cell therapy market is segmented into personalized medicine diagnostics, personalized medical care, personalized medicine therapeutics, and personalized nutrition & wellness. The personalized nutrition and wellness segment dominated the largest market revenue share of 48.40% in 2024, driven by its widespread adoption for tailored health recommendations based on genetic, phenotypic, and lifestyle data, enhancing preventive care and long-term health outcomes.

The personalized medicine therapeutics segment is expected to witness the fastest growth rate of 10.2% from 2025 to 2032, fueled by advancements in genomics, decreasing sequencing costs, and increasing demand for targeted therapies, particularly in oncology and complex diseases.

• By Technology

On the basis of technology, the global personalized medicine and cell therapy market is segmented into pharmacogenomics, point-of-care testing, stem cell therapy, pharmacoproteomics, pharmacogenetics, and others. The pharmacogenomics segment is expected to hold the largest market revenue share of 30.2% in 2024, driven by its ability to customize drug treatments based on individual genetic profiles, minimizing adverse reactions and optimizing outcomes in fields such as oncology, cardiology, and psychiatry.

The stem cell therapy segment is anticipated to witness significant growth from 2025 to 2032, propelled by innovations in regenerative medicine and increasing applications in treating chronic and rare diseases, supported by advancements in cellular technologies.

• By Application

On the basis of application, the global personalized medicine and cell therapy market is segmented into oncology, antiviral (infectious diseases), immunology and autoimmune diseases, neurology, cardiovascular diseases, psychiatry, and others. The oncology segment dominated the market with a 40.2% revenue share in 2024, driven by the rising prevalence of cancer and the adoption of targeted therapies, immunotherapies, and genomic analysis for early detection and treatment.

The immunology and autoimmune diseases segment is expected to experience the fastest growth rate of 10.2% from 2025 to 2032, fueled by the increasing prevalence of autoimmune disorders and advancements in personalized immunotherapies, such as biologics and immune checkpoint inhibitors.

• By End-User

On the basis of end-user, the global personalized medicine and cell therapy market is segmented into hospitals, diagnostic centers, research and academic institutes, and others.The hospitals segment held the largest market revenue share of 45.9% in 2024, driven by the integration of targeted therapies and genomic diagnostics into clinical workflows, enhancing patient outcomes and fostering innovation in precision medicine.

The diagnostic centers segment is anticipated to witness robust growth from 2025 to 2032, propelled by the increasing adoption of advanced diagnostic tools, such as next-generation sequencing (NGS) and companion diagnostics, for personalized treatment planning.

Personalized Medicine and Cell Therapy Market Regional Analysis

• North America dominated the personalized medicine and cell therapy market with a revenue share of 40.01% in 2024, driven by early adoption of precision medicine, robust healthcare infrastructure, high investment in research and development, and the presence of leading biotech companies
• Consumers and healthcare providers prioritize personalized medicine and cell therapies for tailored treatment plans, improved patient outcomes, and reduced side effects, particularly in oncology and chronic disease management
• Growth is supported by technological advancements in pharmacogenomics, stem cell therapy, and point-of-care testing, alongside increasing integration in clinical settings and rising demand in both diagnostic and therapeutic applications

U.S. Personalized Medicine and Cell Therapy Market Insight

The U.S. smart lock market captured the largest revenue share of 81.9% in 2024 within North America, fueled by robust healthcare systems, strong regulatory support from the FDA, and growing awareness of personalized treatment benefits. The trend toward precision diagnostics and targeted therapies, particularly in oncology and cardiovascular diseases, drives market expansion. The integration of advanced technologies such as pharmacogenomics and stem cell therapy in clinical practice, combined with significant investments in biotech, further accelerates growth.

Europe Personalized Medicine and Cell Therapy Market Insight

The Europe personalized medicine and cell therapy market is expected to witness significant growth, driven by increasing regulatory support for precision medicine and growing investments in research. Consumers and healthcare providers seek solutions that enhance treatment efficacy and patient safety, particularly in oncology and autoimmune diseases. Growth is prominent in countries such as Germany and the U.K., where advanced healthcare systems and rising focus on personalized diagnostics support market expansion.

U.K. Personalized Medicine and Cell Therapy Market Insight

The U.K. market is expected to witness rapid growth, driven by increasing adoption of personalized medicine in clinical settings and strong government support for biotech innovation. Demand for pharmacogenomics and stem cell therapies is rising due to their potential to improve patient outcomes in oncology and neurology. In addition, growing awareness of personalized nutrition and wellness solutions encourages market adoption, supported by evolving regulatory frameworks.

Germany Personalized Medicine and Cell Therapy Market Insight

Germany is expected to witness rapid growth in the personalized medicine and cell therapy market, attributed to its advanced biotech sector and high focus on precision medicine. German healthcare providers prioritize technologies such as pharmacoproteomics and stem cell therapy to enhance treatment outcomes and reduce healthcare costs. The integration of these solutions in hospitals and research institutes, along with strong academic-industry collaborations, supports sustained market growth.

Asia-Pacific Personalized Medicine and Cell Therapy Market Insight

The Asia-Pacific region is expected to witness the fastest growth rate, driven by expanding healthcare infrastructure, rising disposable incomes, and increasing adoption of precision medicine in countries such as China, India, and Japan. Growing awareness of personalized diagnostics, therapeutics, and wellness solutions boosts demand. Government initiatives promoting healthcare innovation and patient-centric care further accelerate the adoption of advanced technologies such as pharmacogenomics and stem cell therapy.

Japan Personalized Medicine and Cell Therapy Market Insight

Japan’s personalized medicine and cell therapy market is expected to witness rapid growth due to strong consumer demand for high-quality, targeted treatments and advanced healthcare technologies. The presence of major biotech companies and government support for regenerative medicine, particularly stem cell therapy, drives market penetration. Rising interest in personalized diagnostics and therapeutics for oncology and cardiovascular diseases also contributes to growth.

China Personalized Medicine and Cell Therapy Market Insight

China holds the largest share of the Asia-Pacific personalized medicine and cell therapy market, propelled by rapid urbanization, increasing healthcare expenditure, and growing demand for precision medicine solutions. The country’s expanding middle class and focus on innovative healthcare technologies support the adoption of pharmacogenomics, point-of-care testing, and stem cell therapies. Strong domestic biotech capabilities and competitive pricing enhance market accessibility.

Personalized Medicine and Cell Therapy Market Share

The personalized medicine and cell therapy industry is primarily led by well-established companies, including:

• Abbott (U.S.)
• AbbVie Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Amgen, Inc. (U.S.)
• Astellas Pharma, Inc. (Japan)
• AstraZeneca plc (U.K.)
• Asuragen, Inc. (U.S.)
• Bayer AG (Germany)
• Biogen Inc. (U.S.)
• Bristol-Myers Squibb Co (BMS) (U.S.)
• Danaher Corporation (U.S.)
• Eli Lilly and Company (U.S.)
• Exact Sciences Corporation (U.S.)
• Exagen Inc. (U.S.)
• GE Healthcare (U.S.)
• Genentech, Inc. (U.S.)
• GlaxoSmithKline Plc (U.K.)
• Illumina, Inc. (U.S.)
• Johnson & Johnson (U.S.)

What are the Recent Developments in Global Personalized Medicine and Cell Therapy Market?

• In July 2025, the U.S. FDA granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo and AstraZeneca for ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab as a first-line treatment for adults with HER2-positive metastatic breast cancer. This recognition was based on compelling results from the DESTINY-Breast09 Phase 3 trial, which demonstrated a median progression-free survival of over three years, significantly improving upon the long-standing standard of care
• In June 2025, the U.S. FDA granted accelerated approval to DATROWAY (datopotamab deruxtecan-dlnk), developed by Daiichi Sankyo, marking it as the first TROP2-directed therapy for adults with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC). This milestone introduces a novel precision medicine for patients who have progressed after EGFR-targeted therapy and platinum-based chemotherapy. The approval was based on promising efficacy data from the TROPION-Lung05 and TROPION-Lung01 trials, including a 45% objective response rate and a median duration of response of 6.5 months
• In March 2025, Bharat Biotech unveiled a USD 75 million investment to establish India’s first vertically integrated Cell and Gene Therapy (CGT) facility in Genome Valley, Telangana. This 50,000-square-foot plant marks the company’s strategic expansion beyond vaccines into advanced therapies targeting oncology and rare diseases. Equipped for high-titer viral vector production, the facility will support innovations such as CD19 CAR T cell therapy and gene therapy platforms. Bharat Biotech aims to democratize access to these cutting-edge treatments, with multiple products expected to launch within three years, reinforcing its commitment to affordable, precision medicine
• In March 2025, Alcon acquired a majority stake in Aurion Biotech, Inc., a clinical-stage company pioneering cell therapies for eye diseases. This strategic move supports the advancement of AURN001, Aurion’s allogeneic cell therapy candidate for corneal edema secondary to corneal endothelial disease, into Phase 3 clinical trials. Aurion will operate independently with full backing from Alcon, leveraging its global R&D, regulatory, and commercial capabilities. The therapy has received Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the U.S. FDA, highlighting its potential to transform treatment for vision-threatening conditions
• In January 2025, YASKAWA Electric Corporation and Astellas Pharma Inc. finalized an agreement to establish a joint venture focused on developing a cell therapy manufacturing platform. The initiative will harness robotics innovation, particularly the dual-arm robot “Maholo”, created by YASKAWA’s Robotic Biology Institute. By integrating Maholo’s precision automation with Astellas’ expertise in cell therapy R&D, the venture aims to overcome manufacturing challenges and enhance reproducibility, scalability, and efficiency. The platform will also be accessible to startups and academic institutions, fostering broader innovation in regenerative medicine and advanced therapies

SKU-74435